Your session is about to expire
← Back to Search
Glutamate Receptor Antagonist
Dipraglurant for Parkinson's Disease
Phase 2 & 3
Waitlist Available
Research Sponsored by Addex Pharma S.A.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline (day 1) to week 52
Awards & highlights
Study Summary
This trial will study the long-term effects of a drug called dipraglurant on patients with Parkinson's disease.
Eligible Conditions
- Parkinson's Disease
- Dyskinesia
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline (day 1) to week 52
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline (day 1) to week 52
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Long-term safety and tolerability of dipraglurant as measured by incidence of adverse events
Secondary outcome measures
Evaluate the continued utility of dipraglurant on dyskinesia as assessed by a change-from-baseline score on the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS).
Trial Design
1Treatment groups
Experimental Treatment
Group I: Dipraglurant TIDExperimental Treatment1 Intervention
Find a Location
Who is running the clinical trial?
Addex Pharma S.A.Lead Sponsor
7 Previous Clinical Trials
1,018 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You cannot take amantadine or amantadine ER during the study.You are taking memantine during the study.You have already participated in a specific study for dipraglurant and may benefit from continuing with the treatment in an open-label study.You cannot use marijuana or other cannabis products for the first 4 weeks of the study.You need to take levodopa at least 3 times a day for the whole study.
Research Study Groups:
This trial has the following groups:- Group 1: Dipraglurant TID
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger